Preparation of pharmaceutically acceptable atorvastatin...

Details Preparation of pharmaceutically acceptable atorvastatin... Preparation of pharmaceutically acceptable atorvastatin...

2006-07-11

2006-07-11

Saeed, Kamal A. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07074940

ABSTRACT:
Non-crystalline, in particular amorphous, pharmaceutically acceptable atorvastatin salts, especially the calcium salt, are prepared from atorvastatin lactone or from a compound of formula (I)where A denotes a common protecting group or separate protecting groups for the two hydroxy groups, and B denotes a carboxylic acid protecting group, without the need of prior formation of atorvastatin lactone, the crystalline form of the atorvastatin salt, or a mixture of amorphous and crystalline forms of the atorvastatin salt. Pharmaceutical formulations are prepared from these salts.

REFERENCES:
patent: 4681893 (1987-07-01), Roth
patent: 5003080 (1991-03-01), Butler et al.
patent: 5097045 (1992-03-01), Butler et al.
patent: 5103024 (1992-04-01), Millar et al.
patent: 5124482 (1992-06-01), Butler et al.
patent: 5149837 (1992-09-01), Butler et al.
patent: 5155251 (1992-10-01), Butler et al.
patent: 5216174 (1993-06-01), Butler et al.
patent: 5245047 (1993-09-01), Butler et al.
patent: 5273995 (1993-12-01), Roth
patent: 5280126 (1994-01-01), Butler et al.
patent: 5298627 (1994-03-01), Butler et al.
patent: 5342952 (1994-08-01), Butler et al.
patent: 5397792 (1995-03-01), Butler et al.
patent: 5969156 (1999-10-01), Briggs et al.
patent: 6087511 (2000-07-01), Lin et al.
patent: 6121461 (2000-09-01), McKenzie
patent: 6274740 (2001-08-01), Lin et al.
patent: 0 330 172 (1989-08-01), None
patent: WO 94/20492 (1994-09-01), None
patent: WO 97/03958 (1997-02-01), None
patent: WO 97/03959 (1997-02-01), None
patent: WO 97/03960 (1997-02-01), None
patent: WO 00/71116 (2000-11-01), None
Baumann et al., “The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase”, Tetrahedron Letters, 33(17), 2283-2284 (1992).
Konno et al., “Physical and chemical changes of medicinals in mixtures with absorbents in the solid state. IV.1) Study on reduced-pressure mixing for practical use of amorphous mixtures of flufenamic acid”, Chem. Pharm. Bull., 38(7), 2003-2007 (1990).

Affiliated with

Also associated with

Rating

Preparation of pharmaceutically acceptable atorvastatin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Preparation of pharmaceutically acceptable atorvastatin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of pharmaceutically acceptable atorvastatin... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3524401